Comments
NATCO Pharma (Canada) Inc, a wholly-owned subsidiary of India’s NATCO Pharma Limited, has invested $8 million in eGenesis, Inc, a US-based biotechnology company specializing in xenotransplantation. The investment, announced on September 4, 2024, aims to support eGenesis’s development of human-compatible organs for transplant.
The shares of NATCO Pharma Limited were trading at ₹1,524.80 down by ₹5.80 or 0.38 per cent on the NSE today at 12.05 pm
eGenesis recently made headlines in March 2024 for conducting the world’s first porcine kidney transplant in a living patient, authorized by the FDA under the Expanded Access pathway. The company’s EGEN™ Platform uses genome engineering to address cross-species incompatibilities and viral risks in organ transplantation.
NATCO Pharma’s CEO, Rajeev Nannapaneni said, “We are excited to get involved with eGenesis, Inc. with respect to their pioneering work in xenotransplantation. We agree with the vision of eGenesis that xenotransplantation technology has the potential to end the global transplant shortage and transforming the treatment of organ failure by eliminating waitlist mortality.”
The investment is expected to be completed by September 30, 2024, with NATCO acquiring 4,06,29,761 shares in eGenesis.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.